The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.

MLA

Subramanian, Janakiraman, et al. “The Rate of Occurrence, Healthcare Resource Use and Costs of Adverse Events among Metastatic Non-Small Cell Lung Cancer Patients Treated with First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.” Lung Cancer (Amsterdam, Netherlands), vol. 138, Dec. 2019, pp. 131–38. EBSCOhost, https://doi.org/10.1016/j.lungcan.2019.07.021.

APA

Subramanian, J., Fernandes, A. W., Laliberté, F., Pavilack, M., DerSarkissian, M., & Duh, M. S. (2019). The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer (Amsterdam, Netherlands), 138, 131–138. https://doi.org/10.1016/j.lungcan.2019.07.021

Chicago

Subramanian, Janakiraman, Ancilla W Fernandes, François Laliberté, Melissa Pavilack, Maral DerSarkissian, and Mei Sheng Duh. 2019. “The Rate of Occurrence, Healthcare Resource Use and Costs of Adverse Events among Metastatic Non-Small Cell Lung Cancer Patients Treated with First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.” Lung Cancer (Amsterdam, Netherlands) 138 (December): 131–38. doi:10.1016/j.lungcan.2019.07.021.